Screening/Washout

- Primary diagnosis of ADHD with a combined or hyperactive/impulsive subtype
- Baseline ADHD-RS-IV total score ≥28

Open-Label LDX Dose-Optimization Phase

Schedule:
- Start: 30 mg/d
- 7 (±2) days: 30 or 50 mg/d
- At 14 (±2) days: 30, 50, or 70 mg/d

Dosage was increased or decreased until optimal dosage:
- Tolerable AEs
- Reduction of ADHD-RS-IV scores ≥30%
- CGI-I score of 1 or 2

Crossover Phases 1 and 2

Phase 1 (1 week)
- Placebo n=59
- Optimal LDX dose (30, 50, or 70 mg/d) n=58

Phase 2 (1 week)
- Placebo n=56
- Optimal LDX dose (30, 50, or 70 mg/d) n=57